Seshadri Neervannan
Equibles does not estimate personal net worth.
Get an email with a short summary when Tarsus Pharmaceuticals, Inc. publishes a filing, an earnings call transcript or a press release.
Get TARS alertsAbout Seshadri Neervannan
Seshadri Neervannan is recorded as COO at Tarsus Pharmaceuticals, Inc. (TARS). The newest filing on record that lists Seshadri Neervannan as COO at Tarsus Pharmaceuticals, Inc. (TARS) is dated April 28, 2026. The proxy statement of Tarsus Pharmaceuticals, Inc. reports total compensation of $2,628,172 for Seshadri Neervannan in fiscal 2025, including a base salary of $547,000. Disclosed compensation is on record for 4 fiscal years. Tarsus Pharmaceuticals, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Tarsus Pharmaceuticals, Inc. includes Bobak Azamian (CEO and Chairman), Jeffrey S. Farrow (CFO), Leonard Greenstein (CFO) and 7 others.
Affiliation history
-
Current
Start not stated–present
Last confirmed April 28, 2026
Company network
Leadership on record at Tarsus Pharmaceuticals, Inc.
- Bobak Azamian CEO, Chairman
- Jeffrey S. Farrow CFO
- Leonard Greenstein CFO
- Bryan Wahl General Counsel
- Andrew Goldberg Board Member
- Bhaskar Chaudhuri Board Member
- David E.I. Pyott Board Member
- Elizabeth Yeu-Lin, M.D. Board Member
- Katherine Goodrich Board Member
- Rosemary A. Crane Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Tarsus Pharmaceuticals, Inc. (TARS) | Chief Operating Officer | $547,000 | $2,628,172 |
| 2024 | Tarsus Pharmaceuticals, Inc. (TARS) | Chief Operating Officer | $527,333 | $3,194,689 |
| 2023 | Tarsus Pharmaceuticals, Inc. (TARS) | Chief Operating Officer | $500,000 | $1,741,918 |
| 2020 | Tarsus Pharmaceuticals, Inc. (TARS) | Ph.D. . Chief Operating Officer | $199,621 | $2,213,677 |
Recent activity
No call appearances or filed executive changes recorded yet.